je.st
news
Tag: merck
Why Did Merck Spend $4 Billion on a Tiny Biotech Firm?
2014-06-14 11:42:27| Biotech - Topix.net
Merck & Co. Inc. has had its sights set on conquering the hepatitis C market for a long time now, and the recovering drugmaker is hoping that a small Cambridge, Massachusetts-based biotech company, Idenix Pharmaceuticals, Inc. , can help it move forward in the race to develop a serious competitor to Gilead Sciences' blockbuster treatment, Sovaldi.
Merck Launches Global Patient Registry Supporting Expanded Commitment to Real-World Outcomes Research in Type 2 Diabetes
2014-06-13 14:00:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. New Research Initiative Seeks to Identify Unmet Needs and Address Key Gaps in the Management of Type 2 Diabetes WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the launch of a global registry to evaluate the experiences and outcomes of approximately 20,000 patients with type 2 diabetes in real-world settings over three years. The registry is part of Mercks new global research initiative evaluating outcomes of patients with type 2 diabetes in everyday clinical practice. Language: English Contact: Media:Pam Eisele267-305-3558orKim Hamilton908-423-6831 / 908-391-0131orInvestors:Justin Holko908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: type
research
global
expanded
Merck, Pfizer, HSBC could be big winners from shareholder case
2014-06-13 05:55:04| Biotech - Topix.net
Within the next two weeks, the U.S. Supreme Court A is expected to rule in a major case that could make it much harder for shareholders to band together against public companies in securities fraud class actions.
Tags: case
big
winners
shareholder
Merck challenges Gilead with $3.85B hepatitis C acquisition
2014-06-10 05:02:20| Biotech - Topix.net
Merck will spend about $3.85 billion for Idenix Pharmaceuticals, a small company developing hepatitis C medicines that, together with Merck's experimental drugs, could produce lucrative combo therapies that quickly cure most patients with the blood-borne virus afflicting tens of millions.
Tags: challenges
acquisition
hepatitis
merck
Merck to buy Idenix Pharma for $3.85 billion
2014-06-09 15:33:35| Biotech - Topix.net
Merck & Co. says the Cambridge, Massachusetts, company has built a promising portfolio of hepatitis C treatments, including three in clinical testing Merck will spend $24.50 per share in cash for each share, which closed at $7.23 Friday.
Tags: buy
billion
pharma
merck
Sites : [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] next »